{"title":"人工智能在癌症诊断中的应用:改变医疗行业的游戏规则","authors":"Pramit Sahoo, Meghoparna Kundu, Jeenatara Begum","doi":"10.2174/0113892010298852240528123911","DOIUrl":null,"url":null,"abstract":"<p><p>Early cancer identification is essential for increasing survival rates and lowering the disease's burden in today's society. Artificial intelligence [AI]--based algorithms may help in the early detection of cancer and resolve problems with current diagnostic methods. This article gives an overview of the prospective uses of AI in early cancer detection. The authors go over the possible applications of Artificial Intelligence algorithms used for screening risk of malignancy in asymptomatic patients, investigating as well as prioritising symptomatic individuals, and more accurately diagnosing cancer recurrence. In screening programmes, the importance of patient selection and risk stratification is emphasised, and AI may be able to assist in identifying people who are most at risk of acquiring cancer. Aside from pathology slide and peripheral blood analysis, AI can also increase the diagnostic precision of imaging methods like computed tomography [CT] and mammography. A summary of various AI techniques is given in the review, covering more sophisticated deep learning and neural networks and more traditional models like logistic regression. The advantages of deep learning algorithms in spotting intricate patterns in huge datasets and their potential to increase the precision of cancer diagnosis are emphasised by the authors. The ethical concerns surrounding the application of AI in healthcare are also discussed, and include topics like prejudice, data security, and privacy. A review of the models now employed in clinical practice is included along with a discussion of the prospective clinical implications of AI algorithms. Examined are AI's drawbacks and hazards, such as resource requirements, data quality, and the necessity for consistent reporting. In conclusion, this study emphasises the utility of AI algorithms in the early detection of cancer and gives a general overview of the many strategies and difficulties involved in putting them into use in clinical settings.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Artificial Intelligence in Cancer Diagnosis: A Game-Changer in Healthcare.\",\"authors\":\"Pramit Sahoo, Meghoparna Kundu, Jeenatara Begum\",\"doi\":\"10.2174/0113892010298852240528123911\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Early cancer identification is essential for increasing survival rates and lowering the disease's burden in today's society. Artificial intelligence [AI]--based algorithms may help in the early detection of cancer and resolve problems with current diagnostic methods. This article gives an overview of the prospective uses of AI in early cancer detection. The authors go over the possible applications of Artificial Intelligence algorithms used for screening risk of malignancy in asymptomatic patients, investigating as well as prioritising symptomatic individuals, and more accurately diagnosing cancer recurrence. In screening programmes, the importance of patient selection and risk stratification is emphasised, and AI may be able to assist in identifying people who are most at risk of acquiring cancer. Aside from pathology slide and peripheral blood analysis, AI can also increase the diagnostic precision of imaging methods like computed tomography [CT] and mammography. A summary of various AI techniques is given in the review, covering more sophisticated deep learning and neural networks and more traditional models like logistic regression. The advantages of deep learning algorithms in spotting intricate patterns in huge datasets and their potential to increase the precision of cancer diagnosis are emphasised by the authors. The ethical concerns surrounding the application of AI in healthcare are also discussed, and include topics like prejudice, data security, and privacy. A review of the models now employed in clinical practice is included along with a discussion of the prospective clinical implications of AI algorithms. Examined are AI's drawbacks and hazards, such as resource requirements, data quality, and the necessity for consistent reporting. In conclusion, this study emphasises the utility of AI algorithms in the early detection of cancer and gives a general overview of the many strategies and difficulties involved in putting them into use in clinical settings.</p>\",\"PeriodicalId\":10881,\"journal\":{\"name\":\"Current pharmaceutical biotechnology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-06-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current pharmaceutical biotechnology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0113892010298852240528123911\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical biotechnology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113892010298852240528123911","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Artificial Intelligence in Cancer Diagnosis: A Game-Changer in Healthcare.
Early cancer identification is essential for increasing survival rates and lowering the disease's burden in today's society. Artificial intelligence [AI]--based algorithms may help in the early detection of cancer and resolve problems with current diagnostic methods. This article gives an overview of the prospective uses of AI in early cancer detection. The authors go over the possible applications of Artificial Intelligence algorithms used for screening risk of malignancy in asymptomatic patients, investigating as well as prioritising symptomatic individuals, and more accurately diagnosing cancer recurrence. In screening programmes, the importance of patient selection and risk stratification is emphasised, and AI may be able to assist in identifying people who are most at risk of acquiring cancer. Aside from pathology slide and peripheral blood analysis, AI can also increase the diagnostic precision of imaging methods like computed tomography [CT] and mammography. A summary of various AI techniques is given in the review, covering more sophisticated deep learning and neural networks and more traditional models like logistic regression. The advantages of deep learning algorithms in spotting intricate patterns in huge datasets and their potential to increase the precision of cancer diagnosis are emphasised by the authors. The ethical concerns surrounding the application of AI in healthcare are also discussed, and include topics like prejudice, data security, and privacy. A review of the models now employed in clinical practice is included along with a discussion of the prospective clinical implications of AI algorithms. Examined are AI's drawbacks and hazards, such as resource requirements, data quality, and the necessity for consistent reporting. In conclusion, this study emphasises the utility of AI algorithms in the early detection of cancer and gives a general overview of the many strategies and difficulties involved in putting them into use in clinical settings.
期刊介绍:
Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology. In addition, the journal also considers comprehensive studies and research advances pertaining food chemistry with pharmaceutical implication. Areas of interest include:
DNA/protein engineering and processing
Synthetic biotechnology
Omics (genomics, proteomics, metabolomics and systems biology)
Therapeutic biotechnology (gene therapy, peptide inhibitors, enzymes)
Drug delivery and targeting
Nanobiotechnology
Molecular pharmaceutics and molecular pharmacology
Analytical biotechnology (biosensing, advanced technology for detection of bioanalytes)
Pharmacokinetics and pharmacodynamics
Applied Microbiology
Bioinformatics (computational biopharmaceutics and modeling)
Environmental biotechnology
Regenerative medicine (stem cells, tissue engineering and biomaterials)
Translational immunology (cell therapies, antibody engineering, xenotransplantation)
Industrial bioprocesses for drug production and development
Biosafety
Biotech ethics
Special Issues devoted to crucial topics, providing the latest comprehensive information on cutting-edge areas of research and technological advances, are welcome.
Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.